Rheumatoid Arthritis: Symptoms, Diagnosis, Treatment & Flare Care

Rheumatoid arthritis is a systemic autoimmune disorder in which activated lymphocytes, macrophages, and fibroblast-like synoviocytes sustain synovial inflammation. The synovium hypertrophies into an invasive pannus, erodes cartilage, and drives juxta-articular bone loss that is visible on plain radiographs and ultrasound in established disease. Extra-articular disease—serositis, rheumatoid nodules, interstitial lung disease, Felty spectrum neutropenia, and accelerated atherosclerosis—reminds bedside clinicians that RA is not confined to joints.

Pathophysiology links shared epitope HLA-DRB1 alleles, post-translational citrullination of proteins, and breach of immune tolerance such that anti-citrullinated peptide antibodies (anti-CCP) and RF immune complexes perpetuate complement activation. Cigarette smoke, periodontitis-associated inflammation, and adipokine dysregulation amplify citrullination and innate immune signalling, explaining why smokers often develop more erosive, treatment-refractory courses.

Patients describe insidious small-joint pain, visible hand swelling, difficulty with fine motor tasks, and stiffness that improves only after ≥30–60 minutes of activity—the polar opposite of brief mechanical osteoarthritis gel phenomenon. Constitutional features include low-grade fever, anorexia, and sleep-disrupting fatigue that outstrips what mechanical wear would produce.

Physical examination cues: symmetrical metacarpophalangeal and proximal interphalangeal warmth, boggy swelling, reduced grip, ulnar drift in chronic cases, occasional carpal tunnel compression, and rheumatoid nodules at extensor surfaces. Cervical spine instability is uncommon day-to-day but becomes a peri-operative and trauma concern in long-standing disease, so major airway manipulation should follow local anaesthesia protocols.

Atypical faces: older-onset seronegative patients, palindromic presentations, and predominant lower-extremity knee synovitis can delay recognition; always map symptoms to objective synovitis rather than pain scores alone.

RA arises from gene–environment interplay: HLA-DRB1 shared epitope, family history, female sex, and advancing age elevate risk. Modifiable exposures—especially smoking, periodontal inflammation, obesity, and silicosis in occupational medicine series—speed progression and blunt DMARD response. Hormonal transitions (postpartum flares) and prior seropositivity without arthritis (clinically suspect arthralgia) are contexts where rheumatology often pre-empts structural damage with early csDMARD deployment.

Nurses capture risk data that influences prescribing: viral hepatitis history, latent TB, travel to endemic fungus regions, pregnancy intent, alcohol consumption surrounding methotrexate, and previous infusion reactions—all steer screening before biologics and JAK inhibitors.

Clinical assessment

Rheumatologists emphasise detecting true synovitis—soft tissue swelling with effusion or palpable synovial thickening, warmth, and painful limitation on stress—not bony hypertrophy. Use a structured pain and function history plus objective joint counts. Document baseline disability scores (HAQ or local equivalent) when teams track treatment response over months.

Laboratory investigations

• Anti-CCP antibodies: strongly predictive of persistence and radiographic progression when positive.
• RF: less specific (hepatitis C, chronic infection, other connective tissue disease) but still prognostically useful when high titre.
• CRP & ESR: map inflammatory burden yet may stay normal in treated or limited systemic disease.
• FBC, LFTs, creatinine, hepatitis B/C, lipid profile: baseline and surveillance before DMARD titration.

Pair labs with ANA and overlap features if lupus or Sjögren syndrome is plausible (dry eyes or mouth, photosensitivity, pleuritic pain).

Imaging

Plain radiographs show peri-articular osteopenia, marginal erosions, and joint-space loss in established disease. Musculoskeletal ultrasound reveals power Doppler synovitis early; MRI clarifies occult tenosynovitis or cervical spine involvement when symptoms localize unexpectedly.

Classification criteria scaffold

The 2010 ACR/EULAR criteria weight joint involvement, serology, acute-phase reactants, and symptom duration—useful for trials and structured referral letters even though everyday diagnosis remains clinician-led.

Treatment targets in specialist clinics often aim for low disease activity or remission on composite scores (DAS28-CRP/ESR, CDAI, SDAI). Nurses contribute objective joint counts, patient global scores, and flare narratives at each infusion or day-case review.

↔Narrow screens: swipe sideways to read all columns.

First-line conventional synthetic DMARDs

Methotrexate remains anchor therapy for moderate–high activity RA without contraindications. Weekly oral or subcutaneous dosing, folic acid supplementation (except same-day folic acid per local policy), and structured lab surveillance reduce mucositis, cytopenia, and hepatotoxicity. Pair with short bridging prednisone only while awaiting DMARD effect—taper plans should be explicit to limit osteoporosis and hyperglycaemia.

Combination csDMARDs (triple therapy in selected cohorts) or add-on agents such as sulfasalazine or hydroxychloroquine may appear when monotherapy underperforms—always align with rheumatology and pharmacy because monitoring tables differ.

Biologic & targeted synthetic DMARDs

TNF inhibitors such as infliximab and non-TNF biologics—including IL-6 receptor blockers, B-cell depletors, and co-stimulation modulators—enter when csDMARDs fail, are intolerable, or when prognostic factors demand acceleration. Oral JAK inhibitors add convenience but carry labelled infection and major adverse cardiovascular event discussions; TB and hepatitis screening, lipid checks, and haematologic surveillance mirror biologic pathways.

Nursing checkpoints: verify screening documentation, observe infusion reactions, teach post-injection infection red flags, and reconcile live-vaccine timing with prescribing teams.

Supportive care

Steroid-sparing analgesia, splints during flares, range-of-motion plans, cardiovascular risk factor control, and depression screening integrate with drug ladders.

• Lab cadence: repeat FBC and LFTs every 2–8 weeks during methotrexate titration and at least every 8–12 weeks once stable—more often after illness, new antibiotics, or abnormal trends.
• Infection triggers: pause or modify therapy for serious infection, shingles dissemination, or neutropenic fever per rheumatology bundles.
• Fertility & pregnancy: methotrexate and many biologics require contraception; pre-conception planning must be documented—not a nursing-improvised stop.
• Renal stewardship: dose-adjust csDMARDs with eGFR decline; coordinate with chronic kidney disease (CKD) pathways.
• Referral thresholds: new pulmonary symptoms (progressive dyspnoea), unexplained cytopenia, sustained ALT elevation >2–3× baseline, vision changes on hydroxychloroquine, or neurologic deficits demand rapid clinician review.
• MDT: hand therapists, podiatry, occupational health, and cardiometabolic clinics align when workability or vascular risk dominates.

Articular

• Marginal erosions, tendon rupture, secondary osteoarthritic change after collapse.
• Cervical instability—maintain spinal precautions during tracheal intubation planning.

Systemic

• Rheumatoid nodules, Felty-type neutropenia, secondary amyloidosis (rare).
• Interstitial lung disease—track cough, clubbing, desaturation on exertion.
• Premature atherosclerosis—align blood pressure, lipids, diabetes control.
• Ocular sicca—coordinate with ophthalmology; overlaps with Sjögren spectrum.
• Treatment-related cytopenia, liver injury, or opportunistic infection on biologics/JAK inhibitors.

Clinician-facing prevention centres on early sustained DMARD therapy, smoking cessation, periodontal care, weight optimisation, falls prevention once deformity appears, and bone protection when glucocorticoids exceed brief bridges. Annual influenza vaccination, pneumococcal priming/boosters, COVID-19 boosting, and shingles strategy should align with local immunisation manuals—especially before biologic initiation.

Modern treat-to-target care reduces erosions compared with historical cohorts, yet a sizeable minority still cycles through advanced therapies. Seropositivity, high titre RF/anti-CCP, smoking, obesity, and delayed first DMARD each worsen structural and functional outcomes. Cardiovascular comorbidity now rivals joint damage as a mortality driver—narrate risk plainly when motivating adherence.

Medicines optimisation

Run teach-back on weekly methotrexate timing, foil-capped tablets versus injections, and why low-dose folic acid is not “optional.” Highlight trimethoprim avoidance and escalate potential interactions to pharmacy when acute services add new antibiotics.

Movement & protection

Balance rest during flares with paced strengthening once inflammation cools—refer to physiotherapy for joint protection and energy conservation in persistent pain syndromes that coexist with inflammatory disease.

Bedside checklist before biologic day unit

• Vitals, NEWS2, infection screen (cough, urinary symptoms, dental abscess).
• Confirm screening labs and TB/hepatitis documentation.
• Verify pregnancy status and live vaccine schedule.
• Patent IV line, pre-medications, observation timers, and anaphylaxis kit location.

Initial nursing response: airway/breathing/circulation, secure IV access, blood cultures if febrile, withhold next immunosuppressant dose until reviewed, provide analgesia per protocol, and expedite orthopaedic/rheumatology liaison for joint aspiration when infection is plausible.

Nursing-priority lens (NCSBN Clinical Judgment Measurement Model): recognise cues → analyse cues → prioritise hypotheses → generate solutions → take safe action → evaluate outcomes. These NCLEX-style clinical judgment practice items cover anti-CCP versus RF interpretation, methotrexate stewardship, flare versus sepsis, biologic clinic safety, and treat-to-target reasoning aligned with the Clinical Judgment Measurement Model.